GlassScriptPhysician profile
Rami W Atallah
NPI 1063439099
$3,453.29
in general payments reported to CMS, 2019-2025
24 companies · $42.95 in 2025
The $42.95 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,705 · 2020: $554 · 2021: $137 · 2022: $416 · 2023: $354 · 2024: $244 · 2025: $42.95.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $641.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $641.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,209.86 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $407.46 | 2019-2025 | Breztri, Airsupra |
| Amgen INC. | $326.70 | 2019-2023 | Repatha |
| Shockwave Medical, INC | $227.63 | 2022 | |
| Glaxosmithkline, LLC. | $172.02 | 2019-2021 | |
| Amarin Pharma, INC. | $167.74 | 2019-2020 | |
| Intersect Ent, INC. | $145.83 | 2022 | |
| Bolton Medical INC | $130.00 | 2019 | |
| Idorsia Pharmaceuticals US INC | $85.02 | 2022-2023 | Quviviq |
| Pfizer INC. | $65.00 | 2019 | |
| Astellas Pharma US INC | $64.87 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $64.56 | 2019-2020 | |
| E.R. Squibb & Sons, L.L.C. | $61.94 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $59.18 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $39.71 | 2019 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $37.46 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $36.84 | 2020-2023 | Seglentis, Livalo |
| Radius Health, INC. | $26.79 | 2019 | |
| Janssen Biotech, INC. | $25.81 | 2019 | |
| Lilly USA, LLC | $23.43 | 2024 | Mounjaro |
| Cook Medical LLC | $23.02 | 2025 | Zenith Alpha |
| Novo Nordisk INC | $21.94 | 2020 | |
| Allergan, INC. | $15.63 | 2019 | |
| Alnylam Pharmaceuticals INC. | $14.85 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Rami Atallah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.